Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion increase compared with 2009. North Carolina’s life science companies are certainly part of that mix. A look at the annual reports from public companies in the state shows that many of them are indeed pouring money into R&D. The U.S. […]
Burrill & Co. and the Infinity Group are joining forces to pursue investments in Chinese life science companies. San Francisco-based Burrill, a venture capital/private equity player that's also trying to launch a $1 billion investment fund in Minnesota, and Israel- and China-based Infinity will co-invest in U.S. dollars and Chinese renminbi as equal partners, according to a press release.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Fairly or not, Steve Burrill's reputation in Minnesota will rest a great deal on whether he can deliver the $1 billion investment fund to back the Elk Run BioBusiness Park in Pine Island. He says he's close. But fund or no fund, Burrill said Minnesota already has benefited from his interest and his checkbook.
Burrill is having trouble finding local money for the $500 million of the Elk Run fund that will purchase direct equity stakes in start-ups housed at the planned Elk Run Biosciences Center. So it's no surprise that Coordinate is trying to appeal to the state's sense of economic pride.
Sources say Burrill is nowhere near $1 billion. Depending on whom you ask, Burrill has secured anywhere from zero dollars to $250 million.
The company is in the midst of a Phase 2 trial on an ovarian drug that works with women who have developed resistance to chemotherapy. Data from the study will be available as early as mid-2010.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.